4.5 Article

Relationship of Prior Antidepressant Exposure to Long-Term Prospective Outcome in Bipolar I Disorder Outpatients

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 73, Issue 7, Pages 924-930

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.11m07396

Keywords

-

Funding

  1. Pfizer
  2. National Alliance for Schizophrenia and Depression
  3. National Institute of Mental Health (NIMH)
  4. National Institute of Alcohol Abuse and Alcoholism
  5. Mayo Foundation
  6. AstraZeneca
  7. NIMH
  8. Sunovion
  9. Agency for Healthcare Research Quality
  10. Alkermes
  11. Cephalon
  12. Eli Lilly
  13. Forest Laboratories
  14. GlaxoSmithKline
  15. Jazz Pharmaceuticals
  16. Marriott Foundation
  17. Orodgen Therapeutics
  18. Shire
  19. Takeda Pharmaceutical
  20. Transcept Pharmaceutical
  21. Epi-Q
  22. Orexigen
  23. Netherlands Organisation for Health Research and Development
  24. European Union
  25. Stanley Medical Research Institute
  26. Wyeth
  27. Servier
  28. Medical Research Council, United Kingdom

Ask authors/readers for more resources

Objective:The long-term impact of prior antidepressant exposure on the subsequent course of bipolar illness remains controversial. Method: 139 outpatients (mean age, 42 years) with bipolar I disorder diagnosed by DSM-IV criteria had a detailed retrospective examination of their prior course of illness on the National Institute of Mental Health Life Chart Method. Number of prior antidepressant trials and total duration of antidepressant exposure were assessed. Prospective long-term response (for at least 6 months) to naturalistic treatment in the network from 1996 through 2002 was the primary outcome measure as it related to prior antidepressant exposure (and other illness variables) by logistic regression, with P < .05 used for statistical significance in this post hoc analysis. Results: Greater number of antidepressant trials, but not duration of antidepressant exposure, was related to prospective nonresponse (P=.0051) whether or not antidepressants were covered by concurrent treatment with a mood stabilizer or atypical antipsychotic. Poor prospective response was also independently related to having had an anxiety disorder and 20 or more prior affective episodes. Conclusions: That the number of antidepressant trials, but not duration of antidepressant treatment, was associated with prospective nonresponse suggests that it is the repeated use of antidepressants to treat episodes of depression that is related to poor prospective response to naturalistic treatment. The direction of causality is unclear as to whether more antidepressant trials led to this increased treatment resistance or whether a difficult course of illness with more episodes and anxiety comorbidity engendered more attempts at antidepressant treatment. J Clin Psychiatry 2012;73(7):924-930 (c) Copyright 2012 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available